Adagio Medical Holdings Announces Publication Of Pre-Clinical Results Of Next-Gen Ultra-Low Temperature Ablation Technology To Treat Ventricular Arrhythmias

Adagio Medical Holdings, Inc. (NASDAQ: ADGM) announced the publication of pre-clinical results for its next-generation ultra-low temperature ablation technology aimed at treating ventricular arrhythmias. The study, published in the Journal of Cardiovascular Electrophysiology, highlights significant improvements in catheter performance, including a potential 50-75% reduction in ablation time compared to the first generation vCLAS™ ULTA catheter. The research was conducted by physicians from leading ventricular ablation programs in Germany, Belgium, and Canada.